Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.48
+0.25 (2.71%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $630.00K in the quarter ending June 30, 2026, a decrease of -96.42%. This brings the company's revenue in the last twelve months to $6.19M, down -96.72% year-over-year. In the year 2025, Atara Biotherapeutics had annual revenue of $120.77M, down -6.33%. That makes Atara Biotherapeutics the 39,206th largest company in the world by revenue and 5,189th in the United States.
Revenue (ttm)
$6.19M
Revenue Growth
-96.72%
P/S Ratio
15.36
Revenue / Employee
$619,400
Employees
10
Market Cap
95.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 120.77M | -8.17M | -6.33% |
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ATRA News
- 9 days ago - Atara reports resubmission of tabelecleucel BLA to FDA - TheFly
- 9 days ago - Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration - Business Wire
- 7 weeks ago - Atara Biotherapeutics reports Q2 EPS (32c), consensus (32c) - TheFly
- 1 month ago - Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - Business Wire
- 1 month ago - Atara Biotherapeutics Quarterly report: Q2 2026 - Filings
- 1 month ago - Atara Biotherapeutics Earnings release: Q2 2026 - Filings
- 3 months ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 4 months ago - Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia - GlobeNewsWire